IMRA News and Press, IMARA Inc. From 11/05/20

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 g rant ed Orphan Drug d esignation from European Commission for sickle cell disease Company to host conference...

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...

Imara (IMRA) has dosed the first patient in the Forte Phase 2b trial of IMR-687 for adult patients with beta-thalassemia, a rare inherited red blood cell disorder. Beta-thalassemia presents as a spectrum of disease, with patients categorized based on hemoglobin l...

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first...

Gainers: AgeX Therapeutics (AGE) +260%. Alphatec (ATEC) +36%. CareDx (CDNA) +19%. Selecta Biosciences (SELB) +16%. Tiziana Life Sciences (TLSA) +13%.Losers: Cytokinetics (CYTK) -44%. Taiwan Liposome (TLC) -18%. IMARA (IMRA) -7%. GenMark Diagnostics (GNMK) -6...

Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well. Several companies are set to launch in the shortened holiday week, including software providers Unity Software (U), Snowflake (SNOW), ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic p...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the Company w...

The European Commission has designated Imara's (NASDAQ: IMRA )  IMR-687 as Orphan drug for sickle cell disease. More news on: IMARA Inc., Healthcare stocks news, Read more ...